KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients

[1]  Crispin J. Miller,et al.  Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse , 2019, Nature Medicine.

[2]  K. Pantel,et al.  Liquid biopsy and minimal residual disease — latest advances and implications for cure , 2019, Nature Reviews Clinical Oncology.

[3]  A. Navarro,et al.  Exosome Analysis in Tumor-Draining Pulmonary Vein Identifies NSCLC Patients with Higher Risk of Relapse after Curative Surgery , 2019, Cancers.

[4]  David R. Jones,et al.  A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. , 2018, Journal of the National Cancer Institute.

[5]  K. Spindler,et al.  Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing , 2018, Translational oncology.

[6]  A. Navarro,et al.  Proteomic Analysis of Liquid Biopsy from Tumor-Draining Vein Indicates that High Expression of Exosomal ECM1 Is Associated with Relapse in Stage I-III Colon Cancer1 , 2018, Translational oncology.

[7]  M. Carolan,et al.  Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer , 2018, World journal of gastroenterology.

[8]  K. Haigis.  KRAS Alleles: The Devil Is in the Detail. , 2017, Trends in cancer.

[9]  Stefan Offermanns,et al.  Intravascular Survival and Extravasation of Tumor Cells. , 2017, Cancer cell.

[10]  Masakazu Yamamoto,et al.  KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer , 2017, BMC Cancer.

[11]  R. Booton,et al.  Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[13]  G. Botti,et al.  Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Nicolai J. Birkbak,et al.  Clonal status of actionable driver events and the timing of mutational processes in cancer evolution , 2015, Science Translational Medicine.

[15]  S. Pita-Fernández,et al.  Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[17]  Bruno Landi,et al.  Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[18]  M. Tzardi,et al.  KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer , 2014, PloS one.

[19]  D. Sargent,et al.  KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) , 2014, Clinical Cancer Research.

[20]  G. Cooper,et al.  Colorectal cancer surveillance: what's new and what's next. , 2014, World journal of gastroenterology.

[21]  J. García-Foncillas,et al.  KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients , 2013, Oncology letters.

[22]  S-R Lin,et al.  Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer , 2013, British Journal of Cancer.

[23]  T. Caldés,et al.  Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. , 2012, Clinical colorectal cancer.

[24]  Reiko Nishihara,et al.  Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers , 2012, Clinical Cancer Research.

[25]  J. Tabernero,et al.  Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. , 2012, The oncologist.

[26]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[27]  P. Ghaneh,et al.  Systematic review and meta‐analysis of follow‐up after hepatectomy for colorectal liver metastases , 2012, The British journal of surgery.

[28]  V. Heinemann,et al.  Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status , 2011, Anti-cancer drugs.

[29]  L. Mazutis,et al.  Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. , 2011, Lab on a chip.

[30]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[31]  M. Choti,et al.  Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 Patients , 2009, Annals of surgery.

[32]  Sabine Tejpar,et al.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.

[33]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[34]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Dienemann,et al.  Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. , 2007, The Annals of thoracic surgery.

[36]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[38]  M. Leppert,et al.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.